All In Biotech

Drug Trial Radar · NCT04658472

Proof-of-concept Study for SAR445088 in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

A Phase 2, Multicenter, Open-label, Non-randomized, Proof-of-concept Study Evaluating the Efficacy, Safety, and Tolerability of SAR445088 in Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

Last checked: Nov 19, 2026Latest source record: Nov 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

98

Actual

Start

Apr 28, 2021

Primary completion

Oct 1, 2025

Study completion Oct 1, 2025

Sponsor

Lead sponsor
Bioverativ, a Sanofi companySanofi (SNY)
Sponsor type
Industry
First posted
Dec 8, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Primary Objectives: * Part A: Efficacy of SAR445088 across three subpopulations of CIDP patients: standard of care (SOC)-Treated, SOC-Refractory and SOC-Naive * Part B:Long-term safety and tolerability of SAR445088 in CIDP Secondary Objectives: * Part A: * Safety and tolerability of SAR445088 in CIDP * Immunogenicity of SAR445088 * Efficacy of SAR445088 with overlapping SOC (SOC-Treated group) * Part B: * Durability of efficacy during long-term treatment with SAR445088 in CIDP * Long-term immunogenicity of SAR445088 in CIDP

Conditions

  • Chronic Inflammatory Demyelinating Polyradiculoneuropathy

Interventions

  • SAR445088 (IV)Drug

    Pharmaceutical form: Solution for Injection Route of Administration: Intravenous (IV)

  • SAR445088 (SC)Drug

    Pharmaceutical form: Solution for Injection Route of Administration: Subcutaneous (SC)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Part A: Standard of Care-Treated Only: Percentage of Participants With Relapse After Withdrawal of Standard of Care During the Riliprubart Treatment PeriodTime frame: From Day 1 up to Week 24
  2. Part A: Standard of Care-Refractory Only: Percentage of Participants With Response During the Riliprubart Treatment PeriodTime frame: From Day 1 up to Week 24
  3. Part A: Standard of Care-Naïve Only: Percentage of Participants With Response During the Riliprubart Treatment PeriodTime frame: From Day 1 up to Week 24
  4. Parts A and B: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Treatment-Emergent Serious Adverse Events (SAEs)Time frame: From the first dose of study drug administration (Day 1) until end of the Part B follow-up period, approximately 98 weeks

Locations

28 sites in 10 countries. Site status is shown where the registry gives one.

  • USC Norris Comprehensive Cancer Center- Site Number : 8400004

    Los Angeles, California

  • University of California Irvine - Manchester Pavilion- Site Number : 8400002

    Orange, California

  • University of Kansas Clinical Research Center- Site Number : 8400003

    Fairway, Kansas

  • M Health Fairview University of Minnesota Medical Center - East Bank- Site Number : 8400006

    Minneapolis, Minnesota

  • Columbia University Irving Medical Center- Site Number : 8400005

    New York, New York

  • Investigational Site Number : 1240001

    Gatineau, Quebec, Canada

  • Investigational Site Number : 1240002

    Québec, Quebec, Canada

  • Investigational Site Number : 1560002

    Fuzhou, China

  • Investigational Site Number : 1560001

    Shanghai, China

  • Investigational Site Number : 1560004

    Wuhan, China

  • Investigational Site Number : 2500003

    Bordeaux, France

  • Investigational Site Number : 2500005

    Le Kremlin-Bicêtre, France

  • Investigational Site Number : 2500001

    Marseille, France

  • Investigational Site Number : 2500002

    Nice, France

  • Investigational Site Number : 2760001

    Düsseldorf, Germany

  • Investigational Site Number : 2760002

    Göttingen, Germany

  • Investigational Site Number : 2760004

    Tübingen, Germany

  • Investigational Site Number : 3800003

    Genoa, Genova, Italy

  • Investigational Site Number : 3800001

    Milan, Milano, Italy

  • Investigational Site Number : 3800005

    Rozzano, Milano, Italy

  • Investigational Site Number : 3800002

    Rome, Roma, Italy

  • Investigational Site Number : 5280001

    Amsterdam, Netherlands

  • Investigational Site Number : 6160001

    Lublin, Lublin Voivodeship, Poland

  • Investigational Site Number : 6880001

    Belgrade, Serbia

  • Investigational Site Number : 6880003

    Niš, Serbia

  • Investigational Site Number : 7240003

    Valencia, Spain

  • Investigational Site Number : 7240002

    Barcelona, Barcelona [Barcelona], Spain

  • Investigational Site Number : 7240001

    Barcelona, Catalunya [Cataluña], Spain

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.